Stocks
Axsome Therapeutics (AXSM) R&D/CAPEX US GAAP (year values) |
|||||||||
| 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| R&D/CAPEX, % | 153 068% | 18 879% | 8 253% | 16 829% | 52 975% | ||||
| Changes by years, y/y, % | -179 709pp | -134 190pp | -18 879pp | +8 576pp | -25.2% | ||||
Axsome Therapeutics. R&D/CAPEX, %
Axsome Therapeutics. R&D/CAPEX, changes, pp
Axsome Therapeutics (AXSM) R&D/CAPEX US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| R&D/CAPEX, % | 7 754% | 440 043% | 37 335% | 95 871% | 30 259% | 52 975% | ||
| Changes by years, y/y, % | -14 768pp | +431 919pp | +12 274pp | +80 397pp | +22 505pp | |||
| Changes by quarters, q/q, % | -7 721pp | +432 289pp | -402 708pp | +58 536pp | -65 612pp | |||
